COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    INCMGA 0012-203 - POD1UM-203
Previous Study | Return to List | Next Study

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03679767
Recruitment Status : Recruiting
First Posted : September 20, 2018
Last Update Posted : April 24, 2020
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Condition or disease Intervention/treatment Phase
Metastatic Non-small Cell Lung Cancer Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer Unresectable Melanoma Metastatic Melanoma Locally Advanced Renal Cell Carcinoma Metastatic Clear-Cell Renal Cell Carcinoma Drug: Retifanlimab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Actual Study Start Date : December 19, 2018
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : April 30, 2021

Arm Intervention/treatment
Experimental: INCMGA00012
INCMGA00012 administered to cohorts of specific tumor types.
Drug: Retifanlimab
INCMGA00012 administered intravenously at the recommended Phase 2 dose every 4 weeks.
Other Name: INCMGA00012

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: Up to at least 6 months from the start of treatment ]
    Defined as the percentage of participants having a complete response (CR) or partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the investigator.

Secondary Outcome Measures :
  1. Duration of response [ Time Frame: Up to approximately 3 years ]
    Defined as the time from an initial objective response (CR or PR) according to RECIST v1.1 until first observation of documented disease progression as determined by investigator or death due to any cause.

  2. Disease control rate [ Time Frame: Up to approximately 3 years ]
    Defined as the proportion of participants with either an objective response (CR and PR) or stable disease, according to RECIST v1.1.

  3. Progression-free survival [ Time Frame: Up to approximately 3 years ]
    Defined as the time from the start of therapy until disease progression, as determined by investigator or death due to any cause.

  4. Overall survival [ Time Frame: Up to approximately 3 years ]
    Defined as the time from the start of therapy until death due to any cause.

  5. Number of treatment-emergent adverse events [ Time Frame: Up to approximately 3 years ]
    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

  6. Cmax of INCMGA00012 [ Time Frame: Up to approximately 2 years ]
    Maximum observed plasma or serum concentration.

  7. Tmax of INCMGA00012 [ Time Frame: Up to approximately 2 years ]
    Time to maximum concentration.

  8. Cmin of INCMGA00012 [ Time Frame: Up to approximately 2 years ]
    Minimum observed plasma or serum concentration over the dose interval.

  9. AUC0-t of INCMGA00012 [ Time Frame: Up to approximately 2 years ]
    Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of one of the following: treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and no epidermal growth factor receptor (EGFR), alkaline phosphatase (ALK), or ROS activating genomic tumor aberrations; locally advanced or metastatic urothelial carcinoma in participants who are not eligible for cisplatin therapy and whose tumors express PD-L1 with a combined positive score ≥ 10; unresectable or metastatic melanoma; locally advanced or metastatic renal cell carcinoma with clear cell component (with or without sarcomatoid features) and having received no prior systemic therapy.
  • Measurable disease per RECIST v1.1.
  • Eastern Cooperative Oncology Group performance status 0 to 1.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.
  • Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).
  • Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is > 30 Gy.
  • Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.
  • Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.
  • Laboratory values outside the protocol-defined range at screening.
  • Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.
  • Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
  • Evidence of interstitial lung disease or active noninfectious pneumonitis.
  • Known active central nervous system metastases and/or carcinomatous meningitis.
  • Known active hepatitis B antigen, hepatitis B virus, or hepatitis C virus infection.
  • Active infections requiring systemic therapy.
  • Known to be HIV-positive, unless all of the following criteria are met: CD4+ count ≥ 300/μL, undetectable viral load, receiving antiretroviral therapy.
  • Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
  • Impaired cardiac function or clinically significant cardiac disease.
  • Is pregnant or breastfeeding.
  • Has received a live vaccine within 28 days of the planned start of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03679767

Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463
Contact: Incyte Corporation Call Center (ex-US) +800 00027423

Show Show 52 study locations
Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Study Director: Mark Cornfeld, MD Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT03679767    
Other Study ID Numbers: INCMGA 0012-203
First Posted: September 20, 2018    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
non-small cell lung cancer
urothelial cancer
renal cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases